Figure 4: Resistance rates of P. aeruginosa from 2011–2016. The ordinate shows the relative resistance share of all tested isolates in percent. The cumulative rates for the 4-MRGN and 3-MRGN isolates (17 isolates) were 100% for piperacillin/tazobactam, 70.59% for imipenem, 86.67% for meropenem, 47.06% for ceftazidime, and 63.64% for ciprofloxacin.